These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7700402)

  • 1. [Secondary prevention in patients with a coronary disorder: wider indication for cholesterol-lowering drugs].
    Peters RJ
    Ned Tijdschr Geneeskd; 1995 Mar; 139(12):604-6. PubMed ID: 7700402
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypercholesterolemia: to treat or not to treat? That is the question].
    Ducobu J
    Rev Med Brux; 1994; 15(3):124-31. PubMed ID: 8066357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goals for cholesterol lowering.
    Stankler L
    Circulation; 1999 May; 99(18):2477. PubMed ID: 10318741
    [No Abstract]   [Full Text] [Related]  

  • 4. [Is regression of coronary sclerosis possible?].
    Krayenbühl HP
    Schweiz Rundsch Med Prax; 1993 Nov; 82(47):1348-53. PubMed ID: 8272700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives on statins.
    Mishra TK; Routray S
    J Indian Med Assoc; 2003 Jun; 101(6):381-3. PubMed ID: 14579987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefit of cholesterol-lowering medications after coronary revascularization: a population study.
    Brophy JM; Brassard P; Bourgault C
    Am Heart J; 2005 Aug; 150(2):282-6. PubMed ID: 16086931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence of the efficacy of hypocholesterolemic treatment in primary and secondary prevention of ischemic heart disease].
    Alvarez-Sala Walther LA; Millán Núñez-Cortés J
    Med Clin (Barc); 2000; 114 Suppl 2():1-10. PubMed ID: 10916798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
    Marchioli R; Marfisi RM; Carinci F; Tognoni G
    Arch Intern Med; 1996 Jun; 156(11):1158-72. PubMed ID: 8639010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperlipidemia: decreasing lipid values and effects of statins].
    Mathes P
    Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
    [No Abstract]   [Full Text] [Related]  

  • 12. What do the statins tell us?
    LaRosa JC
    Am Heart J; 2002 Dec; 144(6 Suppl):S21-6. PubMed ID: 12486412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical prevention of coronary heart disease through cholesterol-lowering therapy.
    Grundy SM
    Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799
    [No Abstract]   [Full Text] [Related]  

  • 18. Statins in the prevention of coronary heart disease.
    Williamson DR; Pharand C
    Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM
    Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention in coronary heart disease. Fact: lowering cholesterol saves lives.
    McKenna CJ; Sugrue DD
    Ir Med J; 1995; 88(6):191. PubMed ID: 8575912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.